

Genitourinary Committee

Leadership

Chair: Ian M. Thompson, Jr., MD
 Vice-Chair: Daniel P. Petrylak, MD
 Executive Officer: Christopher W. Ryan, MD
 Statisticians: Cathy M. Tangen, DrPH
 Melissa Plets, MS
 Eddie Mayerson, MS

Scientific Leadership

Translational Medicine: David J. McConkey, PhD (GU Chair)
 Joshua J. Meeks, MD, PhD (Bladder)
 Amir Goldkorn, MD (Prostate)
 Sumanta “Monty” K. Pal, MD (Renal)
 Radiation Oncology: James B. Yu, MD
 Daniel A. Hamstra, MD
 Imaging: Evan Y. Yu, MD
 Hiram Shaish, MD
 John D. Hazle, PhD
 Pathology: M. Scott Lucia, MD
 Surgery: Kelly L. Stratton, MD
 Liaison to the SPORES: Colin P.N. Dinney, MD
 Early Therapeutics: Neeraj Agarwal, MD
 Bladder Organ Site Chairs: Seth P. Lerner, MD (Localized)
 Thomas W. Flaig, MD (Localized)
 Daniel P. Petrylak, MD (Advanced)
 Prostate Organ Site Chairs: Daniel W. Lin, MD (Localized)
 David I. Quinn, MD, PhD (Advanced)
 Renal Organ Site Chairs: Brian Shuch, MD (Localized)
 Ulka N. Vaishampayan, MD (Advanced)

Designates

Cancer Control: Peter J. Van Veldhuizen, Jr., MD
 DEI Champion: Jessica McDermott, MD
 Digital Engagement: Neema Navai, MD
 Veterans Affairs Michael M. Goodman, MD
 Data Coordinators: Jeri Jardine
 Tonya Johnson
 Michele Counts
 Laura Wells
 Oncology Research Professionals:
 CRAs: Abagail L. Cornette, MS
 Cheryl Farlow, RN, OCN
 Nurses: Deborah A. Shaw, RN
 Cheryl Kefauver, RN
 Patient Advocates: Rick Bangs, MBA (Bladder)
 Tony Crispino (Prostate)
 Margaret “Peggy” Zuckerman, MEd (Renal)

Pharmaceutical Science: Joyce Lee, PharmD
 Allison Schepers, PharmD
 Protocol Project Manager: Taj Pereira
 Clinical Trials Program Manager: TBD

Time/Location

GU Committee Part I: Friday, October 21, 2022 2:30 pm - 6:15 pm
 Room: Regency A (Ballroom Level, West Tower)

Time/Location

GU Committee Part II: Saturday, October 22, 2022 9:15 am - 12:15 pm
 Room: Regency A (Ballroom Level, West Tower)

Agenda

GU Committee Part I

2:30 – 2:45 pm: Chair’s Welcome and Opening Remarks. Ian Thompson
 2:45 – 4:00 pm: Prostate Organ Site (Dr. Tanya Dorff and Dr. Daniel Lin)
 4:00 – 5:15 pm: Translational Medicine (Dr. David McConkey)
 5:15 – 6:15 pm: Cancer Control (Dr. Peter Van Veldhuizen)

Prostate

Organ Site Chairs: Dr. Tonya Dorff (Advanced) and Dr. Daniel W. Lin (Local)

Priority Study

S1802, “Phase III Randomized Trial of Standard Systemic Therapy (SST) Versus Standard Systemic Therapy Plus Definitive Treatment (Surgery or Radiation) of the Primary Tumor in Metastatic Prostate Cancer.” Drs. B. Chapin, A. Aparicio, and R. Valicenti. Activated: 9/17/18.

Concepts in Development

S2210, “Targeted neoadjuvant treatment for patients with localized prostate cancer and germline DNA repair deficiency.” Dr. H. Cheng. CTEP Concept approval: 8/2/22.

Active Studies

CTSU/A031102, “A Randomized Phase III Trial Comparing Conventional-Dose Chemotherapy Using Paclitaxel, Ifosfamide, and Cisplatin (TIP) with High-Dose Chemotherapy Using Mobilizing Paclitaxel Plus Ifosfamide Followed by High-Dose Carboplatin and Etoposide (TI-CE) as First Salvage Treatment in Relapsed or Refractory Germ Cell Tumors.” Dr. D. Quinn. Activated: 7/1/15.

Genitourinary Committee

CTSU/EA8171, "Multiparametric MRI (mpMRI) for Preoperative Staging and Treatment Planning for Newly-Diagnosed Prostate Cancer." Dr. M. Liss. Activated: 7/9/18.

CTSU/EA8184, "A Phase II Randomized Double Blinded Study of Green Tea Catechins (GTC) vs. Placebo in Men on Active Surveillance for Prostate Cancer: Modulation of Biological and Clinical Intermediate Biomarkers." Dr. R. Kopp. Activated: 5/10/21.

CTSU/NRG-GU002, "Phase II-III Trial of Adjuvant Radiotherapy and Androgen Deprivation Following Radical Prostatectomy with or Without Adjuvant Docetaxel." Dr. D. Raben. Activated: 12/30/16.

CTSU/NRG-GU008, "Randomized Phase III Trial Incorporating Abiraterone Acetate with Prednisone and Apalutamide and Advanced Imaging into Salvage Treatment for Patients with Node-Positive Prostate Cancer After Radical Prostatectomy (INNOVATE*) *Intensifying Treatment for Node Positive Prostate Cancer by Varying the Hormonal Therapy." Dr. D. Lin. Activated: 3/5/20; Temporarily Closed: 6/24/21; Re-activated: 12/1/21.

CTSU/NRG-GU009, "Parallel Phase III Randomized Trials for High Risk Prostate Cancer Evaluating De-Intensification for Lower Genomic Risk and Intensification of Concurrent Therapy for Higher Genomic Risk with Radiation (PREDICT-RT*)." Dr. S. Zhang. Activated: 10/15/20; Temporarily Closed: 6/24/21; Re-activated: 12/15/21.

Closed Studies

S1216, "A Phase III Randomized Trial Comparing Androgen Deprivation Therapy + TAK-700 with Androgen Deprivation Therapy + Bicalutamide in Patients with Newly Diagnosed Metastatic Hormone Sensitive Prostate Cancer." Drs. N. Agarwal, A. Goldkorn, S. Gupta, et al. Activated: 3/6/13; Permanently Closed: 7/15/17.

CTSU/NRG-GU005, "Phase III IGRT and SBRT Vs IGRT and Hypofractionated IMRT for Localized Intermediate Risk Prostate Cancer." Dr. A. Solanki. Activated: 11/16/17; Closed to accrual: 6/8/22.

CTSU/NRG-GU006, "A Phase II, Double-Blinded, Placebo-Controlled Randomized Trial of Salvage Radiotherapy with or Without Enhanced Anti-Androgen Therapy with Apalutamide in Recurrent Prostate Cancer." Dr. J. Zeng. Activated: 4/27/18; Permanently Closed: 5/19/20.

CTSU/RTOG-0924, "Androgen Deprivation Therapy and High Dose Radiotherapy with or Without Whole-Pelvic Radiotherapy in Unfavorable Intermediate or Favorable High Risk Prostate Cancer: A Phase III Randomized Trial. Dr. T. Marshall. Activated: 7/7/11; Permanently Closed: 6/24/19.

CTSU/NRG-GU007, "Randomized Phase II Trial of Niraparib with Standard Combination Radiotherapy and Androgen Deprivation Therapy (ADT) in High Risk Prostate Cancer (with Initial Phase I) (NADIR*) *Randomized Phase II Trial of Niraparib With Standard Combination Androgen Deprivation Therapy (ADT) and Radiotherapy In High Risk Prostate Cancer (With Initial Phase I)." Dr. D. VanderWeele. Activated: 6/3/19; Temporarily Closed: 5/5/21; Reactivated of dose level 2 (phase I) for 1 additional patient: 9/14/21; Temporarily closed to accrual for phase I dose level 2: 11/4/21; Re-activated to accrual for phase I/dose level 3: 12/6/21; Temporarily Closed: 7/11/2022.

CTSU/EA8153, "Cabazitaxel with Abiraterone Versus Abiraterone Alone Randomized Trial for Extensive Disease Following Docetaxel: The CHAARTED2 Trial." Dr. P. Corn. Activated: 2/8/18; Permanently Closed: 4/2/21; Tobacco use assessment sub-study permanently closed: 10/8/21.

CTSU/AGCT1531, "A Phase 3 Study of Active Surveillance for Low Risk and a Randomized Trial of Carboplatin vs. Cisplatin for Standard Risk Pediatric and Adult Patients with Germ Cell Tumors." Dr. A. D'Souza. Activated: 5/8/17; PRO study Temporarily Closed: 2/12/21.

Translational Medicine

Chair: Dr. David McConkey

Bladder Chair: Dr. Joshua Meeks

Prostate Chair: Dr. Amir Goldkorn

Renal Chair: Dr. Sumanta "Monty" Pal

Cancer Control

Liaison: Dr. Peter J. Van Veldhuizen

Closed Studies

S1600, "A Randomized Phase III Double-Blind Clinical Trial Evaluating the Effect of Immune-Enhancing Nutrition on Radical Cystectomy Outcomes." Drs. J. Hamilton-Reeves and J. Holzbeierlein. Activated: 2/21/19. Temporarily Closed to Accrual: 8/9/2022.

Genitourinary Committee

Agenda

GU Committee Part II

9:15 – 10:30 am: Bladder Organ Site (Dr. Seth Lerner and Dr. Thomas Flaig)

10:30 – 12:15 pm: Renal Organ Site (Dr. Ulka Vaishampayan and Dr. Brian Shuch)

Bladder

Organ Site Chairs: Dr. Thomas Flaig (Advanced) and Dr. Seth Lerner (Local)

Priority Study

S2011, “Randomized Phase II Trial of Gemcitabine, Avelumab, and Carboplatin vs. No Neoadjuvant Therapy Preceding Surgery for Cisplatin Ineligible Muscle-Invasive Urothelial Carcinoma.” Drs. Sonpavde M. Liss, and S. Lerner, et al. Activated: 10/6/21.

Active Studies

S1937, “A Phase III Trial of Eribulin (NSC #707389) with or Without Gemcitabine Versus Standard of Care (Physician’s Choice) for Treatment of Metastatic Urothelial Carcinoma Refractory to, or Ineligible for, Anti PD1/PDL1 Therapy.” Drs. S. Sadeghi and P. Lara. Activated: 2/16/21.

S1806, “Phase III Randomized Trial of Concurrent Chemoradiotherapy with or Without Atezolizumab in Localized Muscle Invasive Bladder Cancer.” Drs. P. Singh, S. Lerner, J. Efstathiou, et al. Activated: 4/19/19.

CTSU/A031701, “A Phase II Study of Dose-Dense Gemcitabine Plus Cisplatin (ddGC) in Patients with Muscle-Invasive Bladder Cancer with Bladder Preservation for Those Patients Whose Tumors Harbor Deleterious DNA Damage Response (DDR) Gene Alterations.” Drs. A. Gupta and S. Gupta. Activated: 8/1/18.

CTSU/A031803, “Phase II Trial of Intravesical Gemcitabine and MK-3475 (Pembrolizumab) in the Treatment of Patients with BCG-Unresponsive Non-Muscle Invasive Bladder Cancer.” Drs. D. Tyson and C. Ramamurthy. Activated: 1/6/20.

CTSU/EA8185, “Phase II Study of Bladder-Sparing Chemoradiation with MEDI4736 (Durvalumab) in Clinical Stage III, Node Positive Bladder Cancer (INSPIRE).” Drs. T. Mitin and J. Meeks. Activated: 8/25/20.

CTSU/EA8192, “A Phase II/III Trial of MEDI4736 (Durvalumab) and Chemotherapy for Patients with High Grade Upper Tract Urothelial Cancer Prior to Nephroureterectomy” Drs. S. Psutka and A. Tripathi. Activated: 5/6/21.

Closed Studies

S1011, “A Phase III Surgical Trial to Evaluate the Benefit of a Standard Versus an Extended Pelvic Lymphadenectomy Performed at Time of Radical Cystectomy for Muscle Invasive Urothelial Cancer.” Drs. S. Lerner, A. Alva, and T. Koppie, et al. Activated: 8/1/11; Permanently Closed: 4/15/17.

S1602, “A Phase III Randomized Trial to Evaluate the Influence of BCG Strain Differences and T Cell Priming with Intradermal BCG Before Intravesical Therapy for BCG Naïve High-Grade Non-Muscle Invasive Bladder Cancer.” Drs. R. Svatek, A. Alva, and S. Lerner. Activated: 2/7/17; Permanently Closed: 12/15/2020.

S1605, “Phase II Trial of Atezolizumab in BCG-Unresponsive Non-Muscle Invasive Bladder Cancer.” Drs. P. Black, P. Singh, and S. Lerner. Activated: 2/7/17; Permanently Closed: 7/5/19.

Renal

Organ Site Chairs: Dr. Ulka Vaishampayan (Advanced) and Dr. Brian Shuch (Local)

Priority Study

S1931, “Phase III Trial of Immunotherapy-Based Combination Therapy with or Without Cytoreductive Nephrectomy for Metastatic Renal Cell Carcinoma (PROBE Trial).” Drs. H. Kim and U. Vaishampayan. Activated: 11/16/20.

Concepts in Development

S2200, “A Phase II Randomized Trial of Cabozantinib (NSC #761968) with or without Atezolizumab (NSC #783608) in Patients with Advanced Papillary Renal Cell Carcinoma (PAPMET2)” Drs. B. Maughan and S. Pal. CTEP Approval on hold: 8/15/22.

Active Studies

CTSU/AREN1721, “A Randomized Phase 2 Trial of Axitinib/Nivolumab Combination Therapy vs. Single Agent Nivolumab for the Treatment of TFE/Translocation Renal Cell Carcinoma (tRCC) Across All Age Groups.” Dr. M. Parikh. Activated: 10/9/18; Temporarily Closed: 3/24/21; Re-activated: 2/7/22.

CTSU/A031704, “PD-Inhibitor (Nivolumab) and Ipilimumab Followed by Nivolumab vs. VEGF TKI Cabozantinib with Nivolumab: A Phase III Trial in Metastatic Untreated Renal Cell Cancer [PDI-GREE].” Dr. T. Zhang. Activated: 5/9/19; Step 1 temporarily closed: 3/8/21; Step 1 re-activated: 3/26/21.

Genitourinary Committee

CTSU/A031801, "A Phase II Randomized Trial of Radium-223 Dichloride and Cabozantinib in Patients with Advanced Renal Cell Carcinoma with Bone Metastasis (Radical)." Dr. M. Parikh. Activated: 12/13/19.

CTSU/A031901, "Duration of Immune Checkpoint Therapy in Locally Advanced or Metastatic Urothelial Carcinoma: A randomized Phase 3 non-Inferiority Trial." Dr. D. Vaena. Activated: 12/10/20.

Closed Studies

S1500, "A Randomized, Phase II Efficacy Assessment of Multiple MET Kinase Inhibitors (Cabozantinib [NSC #761968], Crizotinib [NSC #749005], Savolitinib [NSC #785348], and Sunitinib [NSC #736511]) in Metastatic Papillary Renal Carcinoma (PAPMET)." Drs. S. Pal and P. Lara. Activated 4/5/16; Permanently closed: 12/15/19.

S0931, "EVEREST: Everolimus for Renal Cancer Ensuing Surgical Therapy, A Phase III Study." Drs. C. Ryan, E. Heath, P. Lara, et al. Activated: 4/1/11; Permanently Closed: 9/15/16.

CTSU/E2810, "Randomized, Double-Blind Phase III Study of Pazopanib vs. Placebo in Patients with Metastatic Renal Cell Carcinoma Who Have No Evidence of Disease Following Metastatectomy." Dr. S. Pal. Activated: 8/8/12; Permanently closed: 7/25/17.

CTSU/A031501, "Phase III Randomized Adjuvant study of Pembrolizumab in Muscle Invasive and Locally Advanced Urothelial Carcinoma (AMBASSADOR) Versus Observation." Dr. G. Sonpavde. Activated: 9/21/17; Permanently Closed: 8/24/21.

CTSU/EA8143, "A Phase 3 Randomized Study Comparing Perioperative Nivolumab vs. Observation in Patients with Renal Cell Carcinoma Undergoing Nephrectomy (PROSPER RCC)." Drs. P. Lara and B. Shuch. Activated: 2/2/17; Permanently Closed: 6/9/21.

Diverse Studies of Interest

S1609, "DART: Dual Anti-CTLA-4 and Anti-PD-1 blockade in Rare Tumors." Drs. S. Patel, Y. Chae, R. Kurzrock, et al. Activated: 1/13/17; Permanently Closed: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 13, 14, 15, 16, 17, 18, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 39, 41, 42, 43, 44, 45, 48, 51, 52, and 53; Temporarily Closed: 38, 40, 46, and 51.

CTSU/A031702, "A Phase II Study of Ipilimumab, Cabozantinib, and Nivolumab in Rare Genitourinary Cancers (ICONIC)" Dr. S. Liu. Activated: 4/12/19; Temporarily Closed: Cohort A, B, C, E, F, G, I.

CTSU/EAY 131, "Molecular Analysis for Therapy Choice (MATCH)." Dr. V. Villalobos. Activated: 8/12/15; EAY131 (MATCH) Subprotocol Z1C, EAY131-Z1C, is permanently Closed to Accrual: 5/25/21; EAY131 (MATCH) Subprotocol M, or EAY131-M, is suspended, effective immediately: 8/3/21; AY131 Subprotocols A, C1, C2, E, L, V, Z1E, and Z1G are closed to accrual: 1/31/22; Subprotocol ZIG reactivated: 2/23/22

CTSU/EA8134, "InPACT- International Penile Advanced Cancer Trial (International Rare Cancers Initiative Study)." Dr. C. Pettaway. Activated: 9/8/17.

Genitourinary Committee

Accrual from trial opening through 6/30/2022 by Institution and Study

	S1802	S1806	S1931	S1937	A031102	A031501	A031701	A031702	A031704	A031801	A031803	A031902
Ascension Prov Hosp - Southfield	-	-	-	-	-	-	-	-	1	-	-	-
Banner MD Anderson CC	2	-	-	-	-	-	-	-	-	-	-	-
Banner U Med Ctr - Tucson	6	-	1	-	-	-	-	-	-	-	-	-
Baylor College of Med/Dan L Duncan CCC	2	3	-	-	-	1	-	-	-	-	-	-
CWRU Case CCC LAPS	-	-	-	-	-	-	5	-	-	-	-	3
Ca Res Consort of West Mich NCORP	2	3	-	-	-	-	-	-	-	-	-	-
Ca Res for the Ozarks NCORP	1	1	-	-	-	-	-	-	-	-	-	-
Ca Res of Wisconsin & N Mich Consort	1	4	-	-	-	-	-	-	-	-	-	-
Cedars-Sinai Med Ctr	-	5	1	-	-	-	-	-	-	-	-	-
City of Hope CCC	1	-	-	-	-	-	-	-	-	-	-	-
Columbia U MU NCORP	1	1	-	-	-	3	-	-	-	-	-	-
CommonSpirit Hlth Res Inst	1	4	-	2	-	-	-	-	-	-	-	-
Cotton O'Neil CC / Stormont Vail Hlth	-	-	-	-	-	1	-	-	-	-	-	-
Dayton NCORP	4	1	-	-	-	-	-	-	1	-	-	-
Fred Hutchinson Ca Res Ctr LAPS	11	-	-	-	-	-	-	-	-	-	-	-
Georgia Cares MU NCORP	1	-	-	-	-	-	-	-	-	-	-	-
Gulf South MU NCORP	66	45	1	-	-	2	-	-	-	1	12	-
Hawaii MU NCORP	-	2	-	-	-	-	-	-	-	-	-	-
Heartland Ca Res NCORP	8	6	-	-	-	-	-	-	-	-	-	-
Henry Ford Hosp	19	4	-	-	-	1	-	2	5	-	-	-
Kaiser Permanente NCORP	15	-	-	-	-	14	-	-	45	-	-	-
Lahey Hosp and Med Ctr	-	-	-	-	-	4	-	6	-	-	-	-
Loma Linda U Med Ctr	-	-	-	-	-	2	-	-	-	-	-	-
Loyola U Med Ctr	9	5	1	2	-	-	-	1	1	-	-	-
Massachusetts Vet Epi Res & Info Ctr	-	-	-	-	-	-	-	-	-	-	-	1
Medical U South Carolina MU NCORP	5	-	-	1	-	-	-	-	-	-	-	-
Michigan Ca Res Consort NCORP	7	13	-	1	-	-	-	-	-	-	-	-
Moffitt CC	-	-	-	-	-	-	-	-	-	-	-	-
Montana Cancer Consort NCORP	3	-	-	-	-	-	-	-	-	-	-	-
NCORP Carolinas (Prisma Hlth NCORP)	9	-	-	-	-	-	-	-	1	-	-	-
Nevada Ca Res Foundation NCORP	1	-	-	-	-	-	-	1	-	-	-	-
New Mexico MU NCORP	-	-	-	-	-	-	-	-	-	-	-	-
Northwell Hlth NCORP	-	1	-	-	-	-	-	-	1	-	-	-
Northwestern U LAPS	-	6	-	-	-	-	-	-	1	-	-	-

Genitourinary Committee

Accrual from trial opening through 6/30/2022 by Institution and Study

	S1802	S1806	S1931	S1937	A031102	A031501	A031701	A031702	A031704	A031801	A031803	A031902
Ohio State U CCC LAPS	2	1	-	-	-	-	-	-	-	-	-	-
Oregon Hlth and Science U	-	1	-	-	-	-	-	3	3	-	-	-
SCL Hlth Saint Joseph Hosp	2	-	-	-	-	-	-	-	-	-	-	-
Southeast Clin Onc Res Consort NCORP	3	-	-	-	-	-	-	-	-	-	-	-
Sutter Ca Res Consort	-	2	-	-	-	-	-	-	-	-	-	-
Tulane U Hlth Sciences Ctr	-	-	7	-	-	-	-	-	1	-	-	-
UC Davis CCC LAPS	11	8	-	-	-	4	5	-	2	4	4	-
UC Irvine Hlth/Chao Family CCC	2	4	-	-	-	-	-	-	-	-	-	-
UC San Diego Moores CC	1	1	-	-	-	-	-	-	-	-	-	-
UCLA / Jonsson CCC	-	-	-	-	-	-	-	-	-	-	-	-
USC Norris CCC LAPS	5	-	-	3	12	13	-	4	-	-	-	-
U Alabama Birm/Deep South RC LAPS	-	-	-	-	-	-	-	1	-	1	4	-
U Arkansas for Medical Sciences	1	-	-	-	-	-	-	-	-	-	-	-
U Cincinnati CC-UC Med Ctr	5	4	1	-	-	-	-	-	6	-	-	-
U Colorado CC LAPS	4	5	-	-	-	13	-	-	10	-	-	-
U Kansas CC - MCA Rural MU NCORP	7	4	-	-	-	5	-	1	6	-	-	-
U Kentucky/Markey CC	-	3	-	-	-	-	-	-	-	-	-	-
U Michigan CCC LAPS	2	-	9	-	-	18	-	-	-	-	-	-
U Mississippi Med Ctr	1	-	-	-	-	-	-	1	-	-	-	-
U Oklahoma Hlth Sciences Ctr LAPS	26	14	4	-	-	-	-	-	-	-	-	-
U Rochester LAPS	17	-	1	-	-	-	-	3	5	-	-	-
U Texas Hlth Science Ctr at San Antonio	2	-	2	-	-	-	-	-	-	-	4	-
U Texas MD Anderson CC LAPS	69	-	-	-	-	-	-	-	-	-	-	-
U Utah - Huntsman Ca Inst LAPS	15	-	1	-	-	3	-	-	-	-	-	-
Upstate Carolina Consort NCORP	1	1	-	-	-	-	-	-	-	-	-	-
Vanderbilt U - Ingram CC LAPS	1	2	-	-	-	-	-	-	-	-	-	-
Virginia Mason Med Ctr	-	-	-	-	-	1	-	-	-	-	-	-
Wayne State U - Karmanos Ca Inst LAPS	1	-	-	-	-	-	-	-	-	-	-	-
Western States Ca Res NCORP	-	1	-	-	-	-	-	-	-	-	-	-
Wisconsin NCORP	8	5	-	-	-	-	-	-	-	-	-	-
Yale U - Yale CC LAPS	1	2	-	-	-	8	-	-	-	-	-	-
ALLIANCE	81	18	2	-	-	-	-	-	-	-	-	-
ECOG-ACRIN	56	27	1	-	-	-	-	-	-	-	-	-
NRG	66	86	1	1	-	-	-	-	-	-	-	-
Total	565	293	33	10	12	93	10	23	89	6	24	4

Genitourinary Committee

Accrual from trial opening through 6/30/2022 by Institution and Study

	EA8134	EA8143	EA8153	EA8171	EA8183	EA8191	EA8192	NRGGU002	NRGGU005	NRGGU008	NRGGU009	NRGGU010
Ascension Prov Hosp - Southfield	-	-	-	-	-	-	-	-	-	-	-	-
Banner MD Anderson CC	-	-	-	-	-	-	-	-	-	-	-	-
Banner U Med Ctr - Tucson	-	7	-	-	-	-	-	-	-	-	-	-
Baylor College of Med/Dan L Duncan CCC	-	1	-	-	-	-	-	-	-	-	-	-
CWRU Case CCC LAPS	-	-	-	-	-	-	-	-	-	-	-	-
Ca Res Consort of West Mich NCORP	-	-	-	-	-	-	-	-	-	-	-	-
Ca Res for the Ozarks NCORP	-	-	-	-	-	-	-	-	-	-	-	-
Ca Res of Wisconsin & N Mich Consort	-	-	-	-	-	-	-	-	-	-	-	-
Cedars-Sinai Med Ctr	-	8	-	-	-	-	-	-	-	-	-	-
City of Hope CCC	-	-	-	-	-	-	-	-	-	-	-	-
Columbia U MU NCORP	-	1	-	-	-	-	-	-	-	-	-	-
CommonSpirit Hlth Res Inst	-	4	-	-	-	-	-	-	-	-	-	-
Cotton O'Neil CC / Stormont Vail Hlth	-	-	-	-	-	-	-	-	-	-	-	-
Dayton NCORP	-	1	-	-	-	-	-	-	-	-	-	-
Fred Hutchinson Ca Res Ctr LAPS	-	4	-	-	-	-	-	-	-	-	-	-
Georgia Cares MU NCORP	-	-	-	-	-	-	-	-	-	-	-	-
Gulf South MU NCORP	-	10	-	11	-	-	-	1	1	3	2	-
Hawaii MU NCORP	-	2	-	2	-	-	-	-	-	-	-	-
Heartland Ca Res NCORP	-	-	-	-	-	-	-	-	-	-	-	-
Henry Ford Hosp	-	3	-	-	-	-	-	-	-	-	-	-
Kaiser Permanente NCORP	-	41	10	-	-	-	-	-	-	-	-	-
Lahey Hosp and Med Ctr	-	4	-	-	3	-	-	-	-	-	-	-
Loma Linda U Med Ctr	-	-	-	-	-	-	-	-	-	-	-	-
Loyola U Med Ctr	-	4	-	-	-	-	-	-	-	-	-	-
Massachusetts Vet Epi Res & Info Ctr	-	-	-	-	-	-	-	-	-	-	-	-
Medical U South Carolina MU NCORP	-	-	-	-	-	-	-	-	-	-	-	-
Michigan Ca Res Consort NCORP	-	-	-	-	-	-	-	-	-	-	-	-
Moffitt CC	-	1	-	-	-	-	-	-	-	-	-	-
Montana Cancer Consort NCORP	-	-	-	-	-	-	-	-	-	-	-	-
NCORP Carolinas (Prisma Hlth NCORP)	-	1	-	-	-	-	-	-	-	-	-	-
Nevada Ca Res Foundation NCORP	-	2	-	-	-	-	-	-	-	-	-	-
New Mexico MU NCORP	-	-	-	-	-	-	-	-	1	-	-	-
Northwell Hlth NCORP	-	-	-	-	-	-	-	-	-	-	-	-
Northwestern U LAPS	-	-	-	-	-	-	-	-	-	-	-	-

Genitourinary Committee

Accrual from trial opening through 6/30/2022 by Institution and Study

	EA8134	EA8143	EA8153	EA8171	EA8183	EA8191	EA8192	NRGGU002	NRGGU005	NRGGU008	NRGGU009	NRGGU010
Ohio State U CCC LAPS	-	-	-	-	-	-	-	-	-	-	-	-
Oregon Hlth and Science U	-	14	-	7	-	-	-	-	-	-	-	-
SCL Hlth Saint Joseph Hosp	-	-	-	-	-	-	-	-	-	-	-	3
Southeast Clin Onc Res Consort NCORP	-	-	-	-	-	-	-	-	-	-	-	-
Sutter Ca Res Consort	-	-	-	-	-	-	-	-	2	-	-	-
Tulane U Hlth Sciences Ctr	-	10	-	-	-	-	-	-	1	-	-	-
UC Davis CCC LAPS	-	1	-	-	-	-	-	-	-	-	-	-
UC Irvine Hlth/Chao Family CCC	-	1	-	-	-	-	-	-	-	1	-	-
UC San Diego Moores CC	-	2	-	-	-	-	-	-	-	-	-	-
UCLA / Jonsson CCC	-	8	-	-	-	-	-	-	-	-	-	-
USC Norris CCC LAPS	8	-	-	-	-	-	-	-	-	-	-	-
U Alabama Birm/Deep South RC LAPS	-	6	-	-	-	-	-	-	-	-	-	-
U Arkansas for Medical Sciences	-	-	-	-	-	-	-	-	-	-	-	-
U Cincinnati CC-UC Med Ctr	-	-	-	-	-	-	-	-	-	-	-	-
U Colorado CC LAPS	-	1	-	-	-	-	1	1	1	-	-	-
U Kansas CC - MCA Rural MU NCORP	-	2	1	-	-	-	-	-	-	1	-	-
U Kentucky/Markey CC	-	12	-	-	-	-	-	-	-	-	-	-
U Michigan CCC LAPS	-	-	-	-	-	-	-	-	-	-	-	-
U Mississippi Med Ctr	-	3	2	-	-	-	-	1	-	-	-	-
U Oklahoma Hlth Sciences Ctr LAPS	-	-	-	-	-	1	-	-	-	-	-	-
U Rochester LAPS	-	1	-	-	-	-	-	-	-	-	-	-
U Texas Hlth Science Ctr at San Antonio	-	14	-	50	-	-	-	-	-	-	-	-
U Texas MD Anderson CC LAPS	-	-	8	-	-	-	-	-	-	-	-	-
U Utah - Huntsman Ca Inst LAPS	-	2	8	-	-	-	-	-	-	-	-	-
Upstate Carolina Consort NCORP	-	-	-	-	-	-	-	-	-	-	-	-
Vanderbilt U - Ingram CC LAPS	-	-	-	-	-	-	-	-	-	-	-	-
Virginia Mason Med Ctr	-	-	-	-	-	-	-	-	3	-	-	-
Wayne State U - Karmanos Ca Inst LAPS	-	2	-	-	-	-	-	1	-	-	-	-
Western States Ca Res NCORP	-	-	-	-	-	-	-	-	-	-	1	-
Wisconsin NCORP	-	-	-	-	-	-	-	-	-	-	-	-
Yale U - Yale CC LAPS	-	1	2	-	-	-	-	-	-	-	-	-
ALLIANCE	-	-	-	-	-	-	-	-	-	-	-	-
ECOG-ACRIN	-	-	-	-	-	-	-	-	-	-	-	-
NRG	-	-	-	-	-	-	-	-	-	-	-	-
Total	8	174	31	70	3	1	1	4	9	5	3	3